| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with … M Peeters, TJ Price, A Cervantes, AF Sobrero, M Ducreux, Y Hotko, ... Journal of clinical oncology 28 (31), 4706-4713, 2010 | 1244 | 2010 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1135 | 2018 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 436 | 2019 |
| SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation … GA Van Hazel, V Heinemann, NK Sharma, MPN Findlay, J Ricke, ... Journal of Clinical Oncology 34 (15), 1723-1731, 2016 | 393 | 2016 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 369 | 2017 |
| Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer D Yip, C Karapetis, A Strickland, CB Steer, D Goldstein Cochrane database of systematic reviews, 2006 | 285 | 2006 |
| Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer D Yip, C Karapetis, A Strickland, CB Steer, D Goldstein Cochrane database of systematic reviews, 2006 | 285 | 2006 |
| Final results from a randomized phase 3 study of FOLFIRI±panitumumab for second-line treatment of metastatic colorectal cancer M Peeters, TJ Price, A Cervantes, AF Sobrero, M Ducreux, Y Hotko, ... Annals of Oncology 25 (1), 107-116, 2014 | 251 | 2014 |
| Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial N Pavlakis, KM Sjoquist, AJ Martin, E Tsobanis, S Yip, YK Kang, YJ Bang, ... Journal of Clinical Oncology 34 (23), 2728, 2016 | 227 | 2016 |
| Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic … M Peeters, KS Oliner, TJ Price, A Cervantes, AF Sobrero, M Ducreux, ... Clinical Cancer Research 21 (24), 5469-5479, 2015 | 208 | 2015 |
| Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic … M Peeters, KS Oliner, TJ Price, A Cervantes, AF Sobrero, M Ducreux, ... Clinical Cancer Research 21 (24), 5469-5479, 2015 | 208 | 2015 |
| Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving … GS Patel, K Jain, R Kumar, AH Strickland, L Pellegrini, J Slavotinek, ... Supportive care in cancer 22, 121-128, 2014 | 178 | 2014 |
| Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial NC Tebbutt, MM Cummins, T Sourjina, A Strickland, G Van Hazel, ... British journal of cancer 102 (3), 475-481, 2010 | 133 | 2010 |
| A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma M Peeters, AH Strickland, M Lichinitser, AVS Suresh, G Manikhas, ... British journal of cancer 108 (3), 503-511, 2013 | 90 | 2013 |
| A randomized controlled trial of a nurse-led supportive care package (SurvivorCare) for survivors of colorectal cancer M Jefford, K Gough, A Drosdowsky, L Russell, S Aranda, P Butow, ... The oncologist 21 (8), 1014-1023, 2016 | 78 | 2016 |
| Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy … P Gibbs, V Heinemann, NK Sharma, J Taieb, J Ricke, M Peeters, ... Clinical colorectal cancer 17 (4), e617-e629, 2018 | 67 | 2018 |
| Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro … MM Eatock, NC Tebbutt, CL Bampton, AH Strickland, ... Annals of oncology 24 (3), 710-718, 2013 | 64 | 2013 |
| Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic … M Peeters, KS Oliner, TJ Price, A Cervantes, AF Sobrero, M Ducreux, ... Journal of Clinical Oncology 32 (3_suppl), LBA387-LBA387, 2014 | 61 | 2014 |
| A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma S Halford, D Yip, CS Karapetis, AH Strickland, A Steger, HT Khawaja, ... Annals of Oncology 12 (10), 1399-1402, 2001 | 57 | 2001 |
| Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab NC Tebbutt, F Murphy, D Zannino, K Wilson, MM Cummins, E Abdi, ... Annals of oncology 22 (8), 1834-1838, 2011 | 55 | 2011 |
Timothy PriceThe Queen Elizabeth Hospital and School of Medicine University of AdelaideПідтверджена електронна адреса в adelaide.edu.au
